Therapeutic Interfering Particles Exploiting Viral Replication and Assembly Mechanisms Show Promising Performance: A Modelling Study
Defective interfering particles arise spontaneously during a viral infection as mutants lacking essential parts of the viral genome. Their ability to replicate in the presence of the wild-type (WT) virus (at the expense of viable viral particles) is mimicked and exploited by therapeutic interfering particles. We propose a strategy for the design of therapeutic interfering RNAs (tiRNAs) against positive-sense single-stranded RNA viruses that assemble via packaging signal-mediated assembly. These tiRNAs contain both an optimised version of the virus assembly manual that is encoded by multiple dispersed RNA packaging signals and a replication signal for viral polymerase, but lack any protein coding information. We use an intracellular model for hepatitis C viral (HCV) infection that captures key aspects of the competition dynamics between tiRNAs and viral genomes for virally produced capsid protein and polymerase. We show that only a small increase in the assembly and replication efficiency of the tiRNAs compared with WT virus is required in order to achieve a treatment efficacy greater than 99%. This demonstrates that the proposed tiRNA design could be a promising treatment option for RNA viral infections.
Code (0)
등록된 구현이 없습니다.
Similar Papers 제목 키워드 기반
Quantification of Ebola virus replication kinetics in vitro
Mathematical modelling has successfully been used to provide quantitative descriptions of many viral infections, but for the Ebola virus, which requires biosafety level 4 facilities for experimentation, modelling can pla…
Bayesian InferencePatch formation driven by stochastic effects of interaction between viruses and defective interfering particles
Defective interfering particles (DIPs) are virus-like particles that occur naturally during virus infections. These particles are defective, lacking essential genetic materials for replication, but they can interact with…
Nonsuppressible viremia during HIV-1 therapy meets molecular virology
HIV-1 replication can be suppressed with antiretroviral therapy (ART), but individuals who stop taking ART soon become viremic again. Some people experience extended times of detectable viremia despite optimal adherence …
VirologyOncolytic mechanisms and immunotherapeutic potential of Newcastle disease virus in cancer therapy
Newcastle Disease Virus (NDV), classified as Avian orthoavulavirus 1 (avian paramyxovirus type 1), is a promising oncolytic agent that selectively targets and destroys cancer cells while sparing normal tissues. Its oncos…
Morphology classificationMulti-point Infection Dynamics of Hepatitis B in the Presence of Sub-Viral Particles
Hepatitis B virus (HBV) is considered as etiological agent of the lethal liver disease hepatitis B. Globally, hepatitis B is recognized as one of the prevailing infectious diseases with a significant impact on human heal…